ARTICLE | Clinical News
RAAV2/2_ND4: Phase III amended
September 19, 2016 7:00 AM UTC
GenSight amended the ongoing, double-blind, sham-controlled, international Phase III REVERSE trial evaluating single intravitreal injections of GS010 to include patients ages 15-18. The trial now plan...